46
Views
2
CrossRef citations to date
0
Altmetric
Research Article

INHIBITORY EFFECT OF MAST CELL-MEDIATED ACUTE AND CHRONIC ALLERGIC REACTIONS BY DODUTANG

, , , , , & show all
Pages 583-594 | Published online: 12 Feb 2002
 

ABSTRACT

Dodutang has been used for treatment of various allergic inflammation diseases in Korea. However, it is still unclear how Dodutang prevents these diseases in experimental animal models. Mast cells play an important roles in allergic and other inflammatory reactions by producing a spectrum of powerful mediators including preformed and de novo synthesized cytokines. In this study, we investigated the effect of Dodutang on mast cell-mediated allergic and inflammatory reactions. Dodutang (0.001–5 g/L) significantly inhibited the histamine release from rat peritoneal mast cells activated by compound 48/80. Dodutang (0.001–5 g/kg) dose-dependantly inhibited the passive cutaneous anaphylaxis reaction activated by anti-dinitrophenyl (DNP) IgE in a rat model, especially, by 78.96% at the concentration of 5 g/kg. In addition, Dodutang potently inhibited the secretion of tumor necrosis factor-α (TNF-α), interleukin (IL)-1β in phorbol 12-myristate 13-acetate plus calcium ionophore A23187-stimulated human mast cells. However, IL-6 secretion was enhanced at the same conditions. Dodutang also inhibited the main inflammatory cytokine TNF-α protein expression in human mast cells. These results provide evidences that Dodutang may be beneficial in the treatment of acute and chronic allergic diseases.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.